New Millennium Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

New Millennium Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-10	Closed	-$885	–	431
2023 Q3	$885	Hold	10	–	–	﹤0.01%	334
2023 Q2	$867	Hold	10	–	–	﹤0.01%	352
2023 Q1	$972	Hold	10	–	–	﹤0.01%	360
2022 Q4	$1.03K	Hold	10	–	–	﹤0.01%	368
2022 Q3	$1K	Hold	10	–	–	﹤0.01%	320
2022 Q2	$1K	Buy	+10	New	+$796	﹤0.01%	321

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

New Millennium Group's BMRN Position: Q4 2023 in Review

New Millennium Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2023, closing a stake of 10 shares — an estimated $885 sold.

New Millennium Group first reported a position in BMRN in Q2 2022 and held it in 6 quarters. The position peaked at $1.03K in Q4 2022. 547 funds tracked by Wall St. Rank hold BMRN as of Q4 2023.

New Millennium Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
New Millennium Group sold 10 BioMarin Pharmaceuticals shares in Q4 2023, an estimated $885.
New Millennium Group first reported a position in BioMarin Pharmaceuticals in Q2 2022 and held it in 6 quarters.
New Millennium Group's BioMarin Pharmaceuticals position peaked at $1.03K in Q4 2022.
547 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2023.

Based on New Millennium Group's 13F filing for Q4 2023, filed 17 Jan 2024.